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Imagingofthekidneyandtheheartcanprovidevaluableinformationinthediagnosisandmanagementofcardiorenalsyndromes.
Ultrasound- (US-) based imaging (echocardiogram and renal US) is an essential component in the initial diagnostic workup
of CRS. Echocardiography provides information on the structure and function of heart, and renal ultrasound is useful in
diﬀerentiating between acute and chronic kidney disease and excluding certain causes of acute kidney injury such as obstructive
uropathy. In this paper we overview the basic concepts of echocardiogram and renal ultrasound and will discuss the clinical utility
oftheseimagingtechniquesinthemanagementofcardiorenalsyndromes.Wewillalsodiscusstheroleofotherimagingmodalities
currently in clinical use such as computerized tomography and magnetic resonance imaging as well as novel techniques such as
contrast-enhanced ultrasound imaging.
1.Introduction
The combination of cardiac and renal disease signiﬁcantly
increases the complexity and cost of health care [1]. The
chronic kidney disease associated with heart failure has been
recognized as an independent risk factor for morbidity and
mortality [2–5]. The rate of cardiovascular mortality in the
chronickidneydisease(CKD)populationis10–20timesthat
of those without CKD [6–8]. Recently, the Acute Dialysis
Quality Initiative has published a document describing the
deﬁnition and classiﬁcation of cardiorenal syndrome (CRS)
[1]. According to that document, the term cardiorenal syn-
drome refers to dysfunction of one organ system in presence
of acute or chronic dysfunction of the other. According to
the proposed classiﬁcation, CRS is divided into 5 types.
Types 1 and 2 include those with reduced kidney function
due to either acute (type 1) or chronic cardiac dysfunction,
and CRS 3 and 4 include worsening cardiac function in face
of acute or chronic kidney disease, respectively. Secondary
CRSs are grouped under type 5.
In this paper we will discuss the application of various
imaging modalities in the diagnosis and management of
CRS.
2. Ultrasonography
Imaging using ultrasound waves, ultrasonography, is a
noninvasive, cost-eﬀective, and widely available technology.
The availability of new imaging modalities such as harmonic
imaging, Doppler ultrasound for the study of blood ﬂow,
three-dimensional US and the advances in the technology
and design of new transducers have signiﬁcantly improved
the quality of ultrasound (US) image. Currently, US imaging
is the most widely used imaging modality in many ﬁelds, and
indications for its use are expanding. US examination is con-
sidered the imaging modality of choice in the diagnosis and
management of most cardiac and renal diseases. Therefore,
the main focus of this paper would be on echocardiography
and renal ultrasonography.
The US examination is based on interpretation of the
characterofthereﬂectedsoundwavesfrombodytissues.The
energy and the time lag at which these reﬂected US waves
return and are picked up by the transducers determine the
brightness and the depth of each tissue segment. The design
and frequency of US transducers determine their utility
in clinical imaging. In general, higher frequency probes
generateimageswithhigherresolutionbutbecauseoflimited2 International Journal of Nephrology
tissue penetration, high frequency transducers are used for
imaging of superﬁcial structures. Imaging of the heart and
the kidneys requires frequencies in the range of 2–5MHz
(lower frequencies) to guarantee deeper penetration into the
body. Imaging using ultrasound is limited in presence of gas
and boney structures. High degree of reﬂection of US waves
at the junction of soft tissue and gas or bone results in loss of
signal from tissues beyond that point.
2.1. Echocardiography. Echocardiography is considered the
preferred diagnostic method in cases suspicious of having
heart failure [9]. It is a safe, noninvasive, and reproducible
test applicable at bedside that provides valuable information
on the anatomy and function of the heart. Using echocar-
diography, one can assess the structure of the myocardium
and pericardium, global and regional LV function, and
wall motion at rest and during pharmacologic stress. Two-
dimensional (2D), gray-scale, or B (for brightness) mode
echocardiography provides real-time images of heart struc-
tures and their motion. By imaging the heart in diﬀerent
planes, information on the dimensions, surface area, and
volume of diﬀerent chambers of the heart and valves can
be obtained. M (for motion) mode echocardiography image
is the graphic representation of the movement of cardiac
structures based on the 2D image. Doppler echocardiogra-
phy and color ﬂow imaging provides information on the
blood ﬂow velocities and the pattern of blood ﬂow within
the heart. Pulsed and continuous wave Doppler US provide
information on the velocity of blood ﬂow in a speciﬁc
location or the whole area within the path of ultrasound,
respectively. Color ﬂow Doppler provides information on
velocity, turbulence, and direction of blood ﬂow in the form
of a colorful image superimposed on a 2D image.
Echocardiography provides useful information on left
ventricular (LV) function. These include LV ejection fraction
(LVEF), stroke volume, cardiac index, fractional shortening
and regional wall motion analysis, among others. LVEF is the
fraction of the left ventricular volume at the end of diastole
that is ejected at the end of each contraction. Although there
are objective ways to measure LVEF by plugging in accurate
measurements of LV dimensions or volumes into a formula,
in most cases, LVEF is a visual estimation of LV function and
its accuracy depends on the experience of the interpreter.
In one study of individuals with heart failure and reduced
LVEF 6 months after a myocardial infarction [10], the
overall accuracy of echocardiography in correctly assessing
radionuclide ventriculography LVEF was 86%. In only one
of 86 patients studied, there was a clinically signiﬁcant
diﬀerencebetweenLVEFsestimatedbythetwomethods(low
LVEF by echocardiogram and normal LVEF by radionuclide
technique) [10]. In another study, LVEF estimated by either
echocardiography or electrocardiogram-gated single photon
emission computed tomography (SPECT) were lower than
those obtained by angiography. But they both did similarly
well in accurately assessing LVEF of less than 40% or 35% in
comparisontoangiography[11].Despiteitslimitations[12],
determination of LVEF by 2-dimensional echocardiography
is well accepted as the preferred measure of global LV
function.
Certain echocardiographic parameters such as LV end-
diastolicvolumeindex,mitraldecelerationtime,andseverity
of mitral valve regurgitation are strong predictors of out-
comesinindividualswithadvancedheartfailureandreduced
LVEF [13].
As many as 50% of all cases with clinical symptoms
of heart failure have preserved LV function. Therefore,
assessment of diastolic function in these cases is criti-
cal. Echocardiography is the noninvasive way of assessing
diastolic function. Since almost 80% of LV ﬁlling during
diastole (relaxation of the LV) occurs passively, abnormal
relaxation of myocardium would result in impaired LV
ﬁlling and diastolic dysfunction. M-mode, 2D, and Doppler
echocardiogram are all useful in making the diagnosis of
diastolicdysfunctionandpredictingoutcomes[14].Diastolic
dysfunction can be graded based on the ﬁlling pressures
and mitral inﬂow patterns obtained by echocardiography.
Spectral tissue Doppler-derived index E/E  appears to be
a valuable tool in assessing left atrial pressure [15]. E and
E  represent peak early diastolic mitral ﬂow and mitral
annulusvelocities,respectively.Thisindexhasshownalinear
relationship with LV diastolic pressure irrespective of LVEF,
heart rhythm, and rate [15]. The diagnostic accuracy of
E/E  is similar to that of B-type natriuretic peptide (BNP)
in diagnosis of patients presenting with symptoms of heart
failure with a wide range of LVEF [16].
Septal E/E  at a cut-oﬀ value of 13 in patients presenting
with acute dyspnea and preserved systolic function has a
sensitivity of 76%–82% and speciﬁcity of 88%–91% for
diagnosis of heart failure [17, 18].
2.2.RenalUltrasonography. Kidneysizeandtheechogenecity
of the renal parenchyma provide useful information in the
workupofkidneydiseases.Normalkidneymeasures9–13cm
in long axis. Length of the kidney correlates with height of
the person while kidney volume correlates with weight, body
surface area, and height [19]. Small kidney size is consistent
with chronic kidney disease (CKD). However, not all CKD
cases are associated with small kidneys. Normal or enlarged
kidneys are seen in cases with HIV-associated nephropa-
thy (HIVAN) [20], diabetic nephropathy, and monoclonal
gammapathies.
Within the renal cortex the back scatter of the US waves
occurs mainly from the glomeruli and blood. In general,
normal renal cortex generates an US image that is less
echogenic or darker than the adjacent liver tissue at the same
depth.Increasedechogenecityofrenalcortex,thatis,sameor
brighter than the liver, indicates renal disease. This ﬁnding
on the gray-scale US has a speciﬁcity of 96% and positive
predictive value of 67% for diagnosis of kidney disease
[21].
Since glomeruli occupy only 8% of the cortical volume,
isolated glomerular disease will not produce increased
echogenecity [22]. Increased cortical echogenecity is usually
indicative of CKD. However, echogenic kidneys can also be
seen in cases with acute kidney injury (AKI). As an example,
large and swollen kidneys with increased echogenecity are
reported in cases with acute tubular necrosis (ATN) or lupus
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Ultrasound imaging of the kidneys is very useful in the
diagnosis of obstructive uropathy. In fact, a negative kidney
US exam for hydronephrosis rules out obstruction as the
cause of AKI. When dilatation of calyces and proximal ureter
is found, the diagnosis of urinary tract obstruction can be
made. However, dilatation of renal calyces alone does not
always indicate urinary tract obstruction. In fact, caliceal
dilatation can be found during pregnancy and also in cases
withdiabetesinsipidus[26,27].Dilatationofthedistalureter
may provide clues for presence of obstruction at the level of
bladder or urethra.
3. Role of Ultrasound in
Management of CRS Patients
In patients suspicious of CRS, echocardiogram provides
valuable information on cardiac structure and function and
should be considered as one of the initial diagnostic studies.
Around 27–40% of patients with acute decompensated heart
failure (HF) develop acute kidney injury (AKI) [28]. At
the same time, 45 to 63% of patients with chronic HF
have CKD [29, 30]. Acute decompensated heart failure
can occur in the setting of either systolic or diastolic
dysfunction. Echocardiogram is the most useful diagnostic
test in evaluating the cause of acute HF. In addition to
providing information on systolic and diastolic function of
the heart, echocardiogram is very useful in assessing regional
wall motion abnormalities, condition and function of heart
valves,andhemodynamics.Echocardiogramcanalsobeused
to rule out pericardial disease.
SystolicHFisdeﬁnedascombinationofsymptomsofHF
and LVEF less than 50%. Heart Failure with normal LVEF,
also referred to as diastolic dysfunction, was not recognized
as an entity by the cardiology community until about two
decades ago. Patients with HF and normal LVEF usually
have normal or reduced LV size, but enlarged left atria
[31]. Although it is thought that LVH is the cause of HF
with normal LVEF, the criteria for its diagnosis are only
met in less than 50% of cases with HF and normal EF.
Instead, these individuals have increased LV mass-to-volume
ratio [32]. Doppler echocardiogram can provide valuable
information on LV relaxation, ﬁlling pressures, and stiﬀness.
However, this information needs to be interpreted carefully
with special attention to clinical presentation (acute versus
chronic, presence of symptoms, blood pressure readings,
etc.). The 2007 consensus statement of the Heart Failure and
Echocardiography Associations of the European Society of
Cardiology suggested 3 essential criteria for the diagnosis of
diastolic heart failure or heart failure with normal ejection
fraction. They are presence of signs and symptoms of HF,
normal or mildly abnormal LV size and systolic function
(LVEF > 50% and an LV end-diastolic volume < 97mL/m2),
and evidence of LV diastolic dysfunction via invasive or
noninvasive methods.
Renal ultrasonography is valuable in diﬀerentiating
between acute and chronic kidney disease and ruling out
obstruction as a cause of worsening renal function. In
cases suspicious of type 1 CRS, a normal renal ultrasound
examination is expected. This is due to the acute nature of
condition and the fact that reduced GFR is resulting from
renal hypoperfusion. An exception would be cases in which
acute HF results in acute worsening of GFR from an already
low baseline level, or acute on chronic KD. In these cases,
US features of CKD do not rule out the possibility of CRS
type 1. Availability of previous kidney ultrasound images
for comparison would be of great value in these cases. A
few small single center studies suggest a role for Doppler
ultrasound in the diﬀerential diagnosis of AKI. In one study,
an o r m a l( <0.71) resistive index [(peak systolic velocity −
peak diastolic velocity)/peak diastolic velocity)] measured at
thelevelofsegmentalrenalarterieswasseeninallindividuals
with a low fractional excretion of sodium (FENa), while
individuals with high FENa had high resistive indices [33].
Among those with acute tubular necrosis and high FENa
at baseline, there was a signiﬁcant reduction in the RI after
recovery from AKI episode [33].
4. Other ImagingStudies
4.1. Imaging of the Heart. Although echocardiogram is
considered the imaging modality of choice in the workup
of HF patients, in some cases more information on the
structure and function of the heart might be necessary. In
order to measure LVEF and volumes by echocardiography, a
clear deﬁnition of endocardium is needed. This information
is lacking in as many as 31% of cases [34]. Other imaging
techniques might be needed to obtain more detailed infor-
mation in these cases.
The most commonly used imaging in nuclear car-
diology is single-photon emission computed tomography
(SPECT) imaging of myocardial perfusion. After injection
of the radiotracer, the isotope is extracted from the blood
by viable myocytes and retained within the myocyte for
some period of time. The photons are emitted from the
myocardium which is in proportion to the magnitude of
tracer uptake, and thus relates to perfusion. A gamma
camera captures the photons and converts it into digital data
which represents the magnitude of uptake and location of
emission. Myocardial perfusion scanning using intravenous
injectionoftechnetium-99m-(99mTc-)labeledagentssuchas
sestamibi 99mTc-labeled RBCs can be used for assessment of
LVEF and regional wall motion abnormalities. Radionuclide
imaging can be used to study the structure and function
of the heart at rest and after exercise. LVEF, end-systolic,
and end-diastolic volumes can be accurately measured by
processing three dimensional images on gated SPECT using
99mTc agents [9].
Radionuclide ventriculography can be used to assess
the left ventricular function. It can be performed either as
ﬁrst pass or equilibrium-gated techniques. Both techniques
provide reliable means to asses the left and right ven-
tricular function. The equilibrium technique is referred to
as multiple-gated acquisition (MUGA) scanning. The RVG
technique has advantages over echocardiography as there
are no assumptions made about the ventricular geometry.
Thus radionuclide imaging can provide accurate data about
ventricular function [35].4 International Journal of Nephrology
While there is a high degree of correlation between
measurements of ventricular end-systolic and end-diastolic
volumesmeasuredbygatedSPECTandcardiacMRimaging,
it appears that cardiac MR is superior in providing more
accurate chamber volumes [36, 37].
Positron emission tomography (PET) is used to assess
myocardial viability by assessing its metabolism using FDG
or myocardial perfusion using rubidium (Rb) 82. PET
imaging has several advantages over SPECT, including better
spatial resolution, higher counting eﬃciencies, and excellent
attenuation correction.
Computerized tomography (CT) techniques such as
multi-slice CT and ultrafast electron beam tomography
(EBT) are capable of providing images of the heart with
high temporal and spatial resolutions. Multislice CT obtains
images of the heart in many diﬀerent imaging planes and
is capable of providing information on cardiac volumes
and dimensions. Fast imaging combined with electrocardio-
graphic triggering reduces motion artifacts. EBT imaging
occurs in milliseconds, which resolves the issue of cardiac
motion during imaging. It has been shown to have compa-
rable diagnostic accuracy in diﬀerentiating between ischemic
and nonischemic cardiomyopathy compared to radionuclide
stresstestinginpatientswithHF[38].However,EBTrequires
imaging using contrast for delineation of diﬀerent chambers
for determination of dimensions. This technique is also
associated with high radiation exposure.
As a result of great advancements in the technology
of magnetic resonance imaging, it can now be used for
multiple purposes in evaluation of patients with cardiac
diseases. Cardiac MR (CMR) is useful in assessing cardiac,
great vessels and coronary anatomy and ﬂow, ventricular
function, myocardial viability, and perfusion. CMR provides
the ability of imaging the heart in any desired plane in an
unrestricted view, a clear advantage over echocardiography.
OtheradvantagesofCMRoverechocardiographyincludethe
ease of studying the right ventricle due to its inherent three-
dimensional nature and superior border detection between
ventricular blood pool and the myocardium [34, 39–41].
Cardiac MR has very high accuracy and reproducibility for
determination of ventricular volumes, stroke volume and
ejection fraction [42, 43]. Using diﬀerent MR sequences or
techniques, it is possible to detect ﬁbrosis, scarring, and
inﬂammation of the myocardium. These advantages have
resulted in making CMR the reference standard for ventricu-
larvolumetricassessment.Infact,inmanyinstitutionswhere
this imaging modality is available, cardiac MR is considered
the alternative diagnostic test to echocardiography in cases
with poor ultrasound images or when myocarditis or
inﬁltrative disease of the heart is suspected [44].
4.2. Imaging of the Kidney. Computerized tomography (CT)
is the preferred imaging technique for the workup of kidney
stones, renal masses, and renal arteries. Modern multide-
tector CT scanners are capable of acquiring thin slices of
large areas of the body in one breath hold. Advancements in
postprocessing techniques have also improved the diagnostic
accuracy of CT scanning. Three-dimensional reconstruction
of images is commonly used without compromising on the
quality of the images. In fact, 3D reconstruction of CT
angiograms has been rapidly omitting the need for catheter
angiography [45, 46].
CT urography has almost completely replaced intra-
venous urograms in diagnosis of small stones and neoplasms
of the kidney, ureters, and the urinary bladder. Filling
defects within the collecting system might suggest a blood
clot, stone, or a neoplasm. Unenhanced helical CT scan
is the gold standard for diagnosing suspected renal colic
secondary to kidney stones. Stones that are radiolucent on
plain ﬁlms are readily detectable by CT. In addition, CT
scan provides valuable information on other signs of urinary
tract obstruction such as hydronephrosis or hydroureter and
streaking around these structures.
Contrast-enhanced CT is used to evaluate the arterial
and venous supply of the kidney, renal parenchyma, and
collecting system. Evaluation of the renal parenchyma occurs
in the 3 phases, cortical phase, nephrographic, and excretory
phase, after injection of the contrast. The detection of
cortical or medullary lesions is best achieved during the
nephrographic phase [47, 48]. CT imaging can also be used
as a functional imaging modality for applications such as
estimationoftheGFR.Ofcoursetheriskofcontrast-induced
nephropathy is one of the main drawbacks of contrast-
enhanced CT imaging, especially in individuals with acute
or chronic kidney disease.
The preferred agent for radionuclide imaging of the
kidneys is 99mTc. It provides good image quality with low
radiation and has a short half-life. 99mTc can be bound
to diethylenetriaminepentaacetic acid (DTPA) for meas-
urement of GFR or mercaptoacetyltriglycine (MAG3) to
measurerenalbloodﬂow.Thisimagingmodalitycanbeused
in the diﬀerential diagnosis of AKI. Kidney uptake of 99mTc-
MAG3 in the ﬁrst 1-2 minutes after injection is reduced in
cases with acute tubular necrosis, while it would be normal
in individuals with prerenal AKI. Renal uptake of the tracer
during the late phase (20 minutes after injection) is expected
tobehighinprerenalAKIaswellasATNbutlowinpostrenal
AKI [49].
The main utility of MR imaging in the study of the
genitourinary tract is in staging of malignancies. Magnetic
resonance angiography may be used to study renal arteries,
but its use is limited because of the risk of nephrogenic
systemic ﬁbrosis in individuals with reduced renal function
[50]. This risk is especially high (up to 20%) in individuals
with AKI [51].
Sonographic imaging of kidneys with color Doppler
and B mode has limited ability to evaluate the intrarenal
arteries and arterioles. Imaging using ultrasound contrast
agent can potentially overcome this limitation. The contrast
agents used in renal US are gas-ﬁlled microbubbles that act
similar to the red blood cells and remain in the intravascular
space. In that regard, they are completely diﬀerent from
contrast-agents used in CT or MRI [52]. Contrast-enhanced
echocardiography has been used in the clinical setting.
A few US contrast agents are approved for the study of
myocardial blood ﬂow in humans. More recently, contrast
enhanced ultrasonography (CEU) has been used in the study
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pharmacologic stimuli in animal models and in human sub-
jects with promising results [53–60]. In some studies CEU
has been superior to color and power Doppler US examina-
tion in determining the cause of AKI [61]. While B mode
US can provide information on structure of the kidneys,
addition of ultrasound contrast agents has the potential of
providing additional information on the pattern and quan-
tityofregionalandtotalRBF[61].Onceapprovedforclinical
use in humans, CEU may be of great value in the work up
of cases suspicious of CRS since altered renal hemodynamics
are thought to be the cause of reduced GFR in these cases.
5. Conclusion
Ultrasound based imaging of the heart (echocardiography)
and the kidney are the methods of choice in the work up
of cases suspicious of CRS. US imaging is safe, noninvasive
and widely available. It provides valuable information on the
structure and function of the heart and the structure of the
kidney. In clinical scenarios in which echocardiography is
not helpful, cardiac MR and radionuclide scintigraphy can
be used to assess LV function and structure. CT scan of the
kidneys and the urinary tract is useful in the diagnosis of
urinary tract obstruction and kidney stones. Contrast-based
CT and MR studies are of limited use in CRS because of
the potential complications. Contrast-enhanced ultrasound
and other new investigational imaging modalities (MR) may
prove to be useful in management of CRS cases.
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